Parinaz Sadat Mahmoudi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Parinaz Sadat Mahmoudi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Hadipour Kelidsari
Department of Clinical Pharmacy, Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran
1 shared publication Ashraf Sadat Hosseini
Hematologic Malignancies Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication- Bita Shahrami
Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Hossein Khalili
Department of Clinical Pharmacy, Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran
1 shared publication Majid Davari
Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy Tehran University of Medical Sciences Tehran Iran
1 shared publication- Mohammad Vaezi
Hematology, Oncology, and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 1 November 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (6)
Therapeutic Plasma Exchange: A Cost‐Consequence Analysis Using Data From a Tertiary Care Hospital
Therapeutic plasma exchange (TPE) is a costly procedure and is commonly used as an effective treatment modality for a range of life‐threatening neurological, hematological, and autoimmune disorders. In this study, both the clinical and economic aspects of TPE were evaluated in hospitalized patients at a tertiary teaching hospital. This cost‐consequence analysis was conducted for 246 patients who received TPE during the hospitalization course. Data were extracted from patients' medical records and the hospital information system. Indications were categorized according to the ASFA 2023 guideline, which classifies indications from Category I to IV based on the strength of supporting evidence. Direct medical costs were estimated using a micro‐costing approach. A binary outcome measure was applied. A favorable outcome was defined as partial or complete recovery, and an unfavorable outcome as no recovery or death. Neurologic disorders and TTP were the predominant indications, with most procedures undertaken for ASFA Category I‐II indications. The median direct cost was 987 million IRR (USD 3464) per patient and 197 million IRR (USD 690) per session, with albumin and apheresis sets together contributing more than three‐quarters of total expenditure. Costs were greater among patients who achieved a favorable clinical outcome. Adverse events were infrequent. TPE is an effective and costly intervention. Optimizing resource utilization may reduce the economic burden, particularly in resource‐limited settings. These findings can inform future planning, cost‐effectiveness and cost‐minimization analyses, managerial decision‐making, and optimization of clinical protocols in line with the ASFA 2023 guideline.
- 1 November 2026
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 41 (6)
Therapeutic Plasma Exchange: A Cost‐Consequence Analysis Using Data From a Tertiary Care Hospital
Therapeutic plasma exchange (TPE) is a costly procedure and is commonly used as an effective treatment modality for a range of life‐threatening neurological, hematological, and autoimmune disorders. In this study, both the clinical and economic aspects of TPE were evaluated in hospitalized patients at a tertiary teaching hospital. This cost‐consequence analysis was conducted for 246 patients who received TPE during the hospitalization course. Data were extracted from patients' medical records and the hospital information system. Indications were categorized according to the ASFA 2023 guideline, which classifies indications from Category I to IV based on the strength of supporting evidence. Direct medical costs were estimated using a micro‐costing approach. A binary outcome measure was applied. A favorable outcome was defined as partial or complete recovery, and an unfavorable outcome as no recovery or death. Neurologic disorders and TTP were the predominant indications, with most procedures undertaken for ASFA Category I‐II indications. The median direct cost was 987 million IRR (USD 3464) per patient and 197 million IRR (USD 690) per session, with albumin and apheresis sets together contributing more than three‐quarters of total expenditure. Costs were greater among patients who achieved a favorable clinical outcome. Adverse events were infrequent. TPE is an effective and costly intervention. Optimizing resource utilization may reduce the economic burden, particularly in resource‐limited settings. These findings can inform future planning, cost‐effectiveness and cost‐minimization analyses, managerial decision‐making, and optimization of clinical protocols in line with the ASFA 2023 guideline.
- Open Access
- 11 November 2024
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 18 (1) , 1-7
Immediate hypersensitivity reactions to parenteral cyclosporine in patients with thalassemia major undergoing hematopoietic stem cell transplantation: a case report and review of the literature
Allogeneic hematopoietic stem cell transplantation is a definitive cure for eligible patients with thalassemia major, and calcineurin inhibitors are essential for preventing graft-versus-host disease. Although invaluable, there are few reports of life-threatening hypersensitivity reactions associated with calcineurin inhibitors. These reactions are generally rare but seem to be more prevalent among patients with thalassemia. Herein, we retrospectively report four cases of patients with thalassemia major who developed hypersensitivity reactions to parenteral cyclosporine. The cases include one 19-year-old Caucasian female and three Caucasian males, aged 17, 10, and 20 years, respectively. The patients exhibited symptoms of varying severity, necessitating different management strategies. The reactions occurred either immediately or within a few minutes after the onset of cyclosporine infusion and were often worsened by rechallenge. In all cases, cyclosporine was eventually replaced with tacrolimus or sirolimus. A comprehensive literature review was conducted to investigate the basis of severe immunoglobulin E-mediated hypersensitivity reactions to calcineurin inhibitors in patients with thalassemia major undergoing hematopoietic stem cell transplantation. Several immunogenic factors may potentially increase the susceptibility of these patients to hypersensitivity reactions to Cremophor-containing medications. While severe reactions to calcineurin inhibitors remain rare, clinicians should be aware of the potential for serious adverse events in patients with thalassemia.
- 11 November 2024
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 18 (1) , 1-7
Open AccessImmediate hypersensitivity reactions to parenteral cyclosporine in patients with thalassemia major undergoing hematopoietic stem cell transplantation: a case report and review of the literature
Allogeneic hematopoietic stem cell transplantation is a definitive cure for eligible patients with thalassemia major, and calcineurin inhibitors are essential for preventing graft-versus-host disease. Although invaluable, there are few reports of life-threatening hypersensitivity reactions associated with calcineurin inhibitors. These reactions are generally rare but seem to be more prevalent among patients with thalassemia. Herein, we retrospectively report four cases of patients with thalassemia major who developed hypersensitivity reactions to parenteral cyclosporine. The cases include one 19-year-old Caucasian female and three Caucasian males, aged 17, 10, and 20 years, respectively. The patients exhibited symptoms of varying severity, necessitating different management strategies. The reactions occurred either immediately or within a few minutes after the onset of cyclosporine infusion and were often worsened by rechallenge. In all cases, cyclosporine was eventually replaced with tacrolimus or sirolimus. A comprehensive literature review was conducted to investigate the basis of severe immunoglobulin E-mediated hypersensitivity reactions to calcineurin inhibitors in patients with thalassemia major undergoing hematopoietic stem cell transplantation. Several immunogenic factors may potentially increase the susceptibility of these patients to hypersensitivity reactions to Cremophor-containing medications. While severe reactions to calcineurin inhibitors remain rare, clinicians should be aware of the potential for serious adverse events in patients with thalassemia.